Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and four have assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $5.40.
Several equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Inhibikase Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. LADENBURG THALM/SH SH upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, July 13th. Oppenheimer began coverage on shares of Inhibikase Therapeutics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $5.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Tuesday, April 21st.
View Our Latest Stock Analysis on IKT
Hedge Funds Weigh In On Inhibikase Therapeutics
Inhibikase Therapeutics Stock Performance
IKT stock opened at $2.11 on Wednesday. The stock has a market cap of $278.58 million, a P/E ratio of -4.91 and a beta of 0.94. The stock’s fifty day simple moving average is $1.83 and its two-hundred day simple moving average is $1.81. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $2.36.
Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). As a group, analysts forecast that Inhibikase Therapeutics will post -0.42 earnings per share for the current fiscal year.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.
Featured Articles
- Five stocks we like better than Inhibikase Therapeutics
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
